Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Weight Gain
Interventions: metformin, healthy lifestyle intervention; Drug · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 10 Years to 17 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia
Interventions: MedActive, Smartphone; Behavioral · Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 64 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: PTSD, Posttraumatic Stress Disorder
Interventions: Not listed
Lead sponsor: Tuscaloosa Research & Education Advancement Corporation; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: Schizophrenia, Schizoaffective Disorder, Weight Gain
Interventions: H218O and 2H2O, administered as a mixed cocktail; Dietary Supplement
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions: Latuda©; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 6 Years to 19 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Metabolic Syndrome X
Interventions: Aripiprazole; Drug
Lead sponsor: New Mexico VA Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Team-Based Quality Improvement Intervention, Opinion Leader Intervention, Team Based Quality Improvement; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Fayetteville, Arkansas • No. Little Rock, Arkansas • Dayton, Ohio + 1 more

Conditions: Bipolar Disorder, Alcohol Dependence
Interventions: Placebo, Quetiapine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Psychotic Depression
Interventions: Aripiprazole; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Weight Gain
Interventions: metformin, placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 10 Years to 17 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia
Interventions: LY2140023, Placebo, Standard of Care; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Garden Grove, California • Chicago, Illinois • Hoffman Estates, Illinois + 1 more

Conditions: Parkinson's Disease
Interventions: cannabidiol; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Schizophrenia
Interventions: ITI-007, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 8 more

Conditions: Schizophrenia
Interventions: Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone; Other · Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 34
States / cities: Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more

Conditions: Combat Disorders, Stress Disorders, Post-Traumatic
Interventions: Open Label (OL) Paroxetine, Placebo, Quetiapine; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Charleston, South Carolina

Conditions: Obesity, Vitamin D Deficiency, Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions: Ergocalciferols; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 10 Years to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Visual Decision Aid and Shared Decision Making Model, Usual Care; Behavioral
Lead sponsor: VA Nebraska Western Iowa Health Care System; Federal
Eligibility: 19 Years to 65 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Schizophrenia
Interventions: Atomoxetine; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Baltimore, Maryland • Catonsville, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Risperidone microspheres, Risperidone, Olanzapine, Quetiapine, Ziprasidone, Aripiprazole, Paliperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 8
States / cities: Los Angeles, California • Augusta, Georgia • Iowa City, Iowa + 5 more

Conditions: Autistic Disorder, Autism
Interventions: Placebo, Risperidone high dose, Risperidone low dose; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 20
States / cities: Dothan, Alabama • Phoenix, Arizona • Sacramento, California + 17 more

Conditions: Major Depressive Disorder, Depression, Depressive Disorder, Depressive Episode, Depression, Unipolar
Interventions: GeneSight Psychotropic test, FDA-approved antidepressant or antipsychotic treatment; Other · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Treatment Resistant Depression
Interventions: Intranasal esketamine; Drug
Lead sponsor: Psych Atlanta; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Marietta, Georgia

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Divalproex Sodium Extended-Release Tablets, placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia
Interventions: Valbenazine, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 13 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: San Jose, California • Coral Gables, Florida • Atlanta, Georgia

Search by objective public record fields.

Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications

Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade

Effects of Antipsychotic Medications on Energy Intake and Expenditure

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

The Effects of Aripiprazole on Patients With Metabolic Syndrome

A Study of Strategies to Improve Schizophrenia Treatment

Quetiapine for Bipolar Disorder and Alcohol Dependence

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

Strategies to Reduce Antipsychotic-Associated Weight Gain in Youth

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease

A Trial to Assess the Antipsychotic Efficacy of ITI-007

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Quetiapine Augmentation for Treatment-resistant PTSD

Vitamin D Supplementation in Psychiatric Illnesses

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy

A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder

Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia